Retatrutide appears to be a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By stimulating these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately contributes to significant reduction in body ma